Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA
Paul E. Goss , James N. Ingle , Kathleen I. Pritchard , Hyman Muss , Julie Gralow , Karen A. Gelmon , Timothy Joseph Whelan , Kathrin Strasser-Weippl , Sheldon Rubin , Keren Sturtz , Antonio C. Wolff , Eric P. Winer , Clifford A. Hudis , Alison Stopeck , J. Thaddeus Beck , Judith Salmon Kaur , Kate Whelan , Dongsheng Tu , Wendy R. Parulekar
Background: Five years of aromatase inhibitor (AI) therapy either as up-front treatment or after 2-5 years of tamoxifen has become the standard of care for postmenopausal women with hormone receptor positive early breast cancer. Extending treatment with an AI to 10 years may further reduce the risk of breast cancer recurrence. Methods: We conducted a double-blind, placebo-controlled trial (Canadian Cancer Trials Group MA.17R) to test the efficacy of extending AI treatment for an additional five years using letrozole. The primary endpoint was disease-free survival. Results: A total of 1,918 women with early stage breast cancer were enrolled (median follow-up 75 months, 6.3 years). A total of 165 disease-free survival (DFS) events (67 on letrozole and 98 on placebo) occurred, of which 42 versus 53 were distant recurrences on letrozole and placebo, respectively. There were 200 deaths (100 in each treatment group). The 5 year DFS was respectively 95% for patients receiving letrozole versus 91% for those on placebo (HR 0.66; P = 0.01) from a two-sided log-rank test stratified by nodal status, prior adjuvant chemotherapy, interval between last dose of AI therapy and randomization, and duration of prior tamoxifen at randomization. The 5 year overall survival was respectively 93% for subjects on letrozole and 94% on placebo with a HR of 0.97 (P = 0.83). The annual incidence rate of contralateral breast cancer was 0.21% for subjects on letrozole versus 0.49% on placebo (P = 0.007). Conclusions: Compared to 5 years of AI treatment as initial therapy or preceded by 2-5 years of tamoxifen, extending AI treatment to 10 years significantly improves disease-free survival. Further analyses will provide a comprehensive picture of toxicities and QOL. Clinical trial information: NCT00754845
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Samantha Myers
2023 ASCO Annual Meeting
First Author: Michael Untch
2016 ASCO Annual Meeting
First Author: Julie Lemieux
2022 ASCO Annual Meeting
First Author: Dawn L. Hershman